BioSpace News Archive

Diaprost announced a publication in the journal of Clinical Cancer Research on PSA-targeted Alpha-, Beta- and Positron Emitting Immuno-Theranostics in Murine Prostate Cancer Models and Non-Human Primates.

The global biotechnology & pharmaceutical services outsourcing market is foreseen to demonstrate notable expansion avenues during the assessment period of 2020 to 2030, highlights an upcoming research report by TMRR.

Gan & Lee Pharmaceuticals Co., Ltd., a global biopharmaceutical company, has announced a collaborative partnership with the International Diabetes Federation that aims to support their global efforts of promoting diabetes care and prevention worldwide.

Kintor Pharmaceutical Limited is pleased to announce that the clinical trial of Proxalutamide for the treatment of hospitalised COVID-19 patients in Brazil completed the recruitment of 588 patients.

LAVA Therapeutics B.V., an early clinical-stage biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers to transform cancer therapy, today announced the appointment of Dr. Kapil Dhingra as chairman of its Board of Directors

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced the appointment of accomplished biotech and pharmaceutical executive, Olivia C. Ware, and fintech and payments thought leader and entrepreneur, Carey O’Connor Kolaja, to its Board of Directors.

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase), a clinical-stage pharmaceutical company developing therapeutics for Parkinson’s disease and related disorders, today announced that it will present findings from its oral therapy studies for its lead agent IkT-148009 in progressive disease models of Parkinson’s at the American Society of Experimental Neurotherapeutics (ASENT) 2021 Annual Meeting

908 Devices Inc., (Nasdaq: MASS) a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it will report financial results for the fourth quarter and full year of 2020 before market open on Tuesday, March 30, 2021.

NovellusDx (or the “Company”), a clinical-stage biotechnology company focused on precision oncology, today announced that it is establishing Fore Biotherapeutics U.S. as its operating company in the United States to reflect its evolved biotech business model focused on matching patients with unaddressed tumor mutations with the right medicines in the clinic.

Havn Life Sciences Inc., a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is pleased to announce that its common shares are now eligible for electronic clearing and settlement through the Depository Trust Company in the United States.